Home
Sonoma Biotherapeutics

Sonoma Biotherapeutics Market Share Analysis for May 2026

Our balanced approach to treating and possibly curing autoimmune and inflammatory disease is similar to our approach to creating a healthy work environment.

Health > Biotechnology and Pharmaceuticals

Domainsonomabio.com

Year Founded2019

Employees51 - 200

Annual Revenue$2M - $5M

Sonoma Biotherapeutics

Sonoma Biotherapeutics (including company regionals)

sonomabio.com

See more website traffic and engagement information

Sonoma Biotherapeutics Revenue up to May 2026 is 2M - 5M

revenue generated by Sonoma Biotherapeutics top domains

Sonoma Biotherapeutics top domains revenue over 3 years

Revenue for Sonoma Biotherapeutics top domains

sonomabio.com2M - 5M

See more with Sales Intelligence

Total visits to Sonoma Biotherapeutics's top domains

Understand Sonoma Biotherapeutics market share and potential market reach.

Total visits last 3 months

Subsidiaries Breakdown

sonomabio.com3.6K

See more with Sales Intelligence

Avg. visit duration in Sonoma Biotherapeutics's top domains

Analyze Sonoma Biotherapeutics engagement metrics.

Average visit duration last 3 months

Subsidiaries Breakdown

sonomabio.com00:00:38

See more with Sales Intelligence

Avg. pageviews on Sonoma Biotherapeutics's top domains

See how Sonoma Biotherapeutics keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

Subsidiaries Breakdown

sonomabio.com1.84

See more with Sales Intelligence

Sonoma Biotherapeutics top competitors by domain

Looks like there’s not enough data here

No Data to Display

Top technologies used by Sonoma Biotherapeutics

These are the website technologies, by industry, used by Sonoma Biotherapeutics top domains

Widget (5)

Twemoji

Mobile (3)

Meta Viewport

Advertising (2)

DoubleClick

Audio Video Media (2)

YouTube

More Technologies

8

See all

News & Signals from Sonoma Biotherapeutics

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsFountain leaves Sonoma Biotherapeutics, Inc. as Vice President and Head of People & Culture.Prior to joining the Academy, Fountain served as Vice President and Head of People & Culture at Sonoma Biotherapeutics, where she architected and led the People function during a pivotal stage of clinical and organizational advancement.

NewsArron leaves Sonoma Biotherapeutics, Inc. as Chief Scientific Officer (CSO) and Head.Dr. Arron joins Calico from Sonoma Biotherapeutics where he served as Chief Scientific Officer (CSO) and Head of R&D overseeing preclinical research and clinical development activities for the company's engineered regulatory T-cell therapy programs.

NewsSonoma Biotherapeutics, Inc. is developing T-cell therapies for the treatment of autoimmune-related disorders on Nov 4th '25.SonomaBio will now expedite the development of a G-Rex-based manufacturing process to develop T-cell (Treg) therapies for the treatment of autoimmune-related disorders.